论文部分内容阅读
目的:评价更昔洛韦对不孕不育女性患者巨细胞病毒(CMV)感染的临床疗效。方法:选取2013年12月—2015年12月收治的不孕不育CMV感染患者60例作为研究对象,以患者入院时间先后将其分为A组和B组,每组30例;A组患者均给予更昔洛韦注射液治疗,B组患者均给予抗巨细胞病毒的免疫球蛋白制剂治疗,比较两组患者治疗后的临床疗效以及不良反应的发生率。结果:治疗后,A组患者的巨细胞病毒(CMV-DNA)和CMV抗体(CMV-IgM)转阴率以及受孕率优于B组患者(P<0.05),不良反应的发生率与B组患者比较其差异无统计学意义(P>0.05)。结论:对不孕不育CMV感染妇女,采用更昔洛韦注射给药治疗的疗效和安全性均较好。
Objective: To evaluate the clinical effect of ganciclovir on cytomegalovirus (CMV) infection in infertile women. Methods: Sixty patients with infertility CMV infection from December 2013 to December 2015 were selected as research objects. Patients were divided into group A and group B, 30 patients in each group. Patients in group A Were given ganciclovir injection treatment, patients in group B were given anti-cytomegalovirus immunoglobulin preparation treatment, the clinical efficacy of the two groups were compared after treatment and the incidence of adverse reactions. Results: After treatment, the negative conversion rate of CMV-CMV and CMV-IgM and the pregnancy rate in group A were better than those in group B (P <0.05). The incidence of adverse reactions in group A was significantly lower than that in group B There was no significant difference in patients (P> 0.05). Conclusion: The efficacy and safety of ganciclovir injection in women with infertility CMV infection are better.